Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Trial Profile

Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Neratinib (Primary)
  • Indications Advanced breast cancer; Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.
    • 12 Feb 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top